NCT03918187View on ClinicalTrials.gov

Intrathecal Nalbuphine Versus Midazolam in Cesarean Section

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

December 1, 2019

Conditions
Cesarean Section Pain
Interventions
DRUG

Bupivacaine

compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

DRUG

Nalbuphine

compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

DRUG

Midazolam

compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Trial Locations (1)

002055

Olfat Abd Elmoniem Ibrahem Amin, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT03918187 - Intrathecal Nalbuphine Versus Midazolam in Cesarean Section | Biotech Hunter | Biotech Hunter